DRKS00015828已完成未知
A placebo-controlled, randomized, single-centre, two-way crossover study to assess choline levels in plasma after a single dose of Superba Boost or choline bitartrate in healthy volunteers - BTS1195/18
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years(—)
- 性别
- All
入选标准
- •Healthy males or females (1:1) aged 18 - 65 years
- •Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less
- •BMI =18 and =30 kg/m²
- •Nonsmoker
排除标准
- •Main exclusion criteria
- •Relevant history or presence of any severe medical disorder, potentially interfering with this study (e.g. mal absorption, chronic gastro-intestinal diseases (colitis ulcerosa, Crohn’s IBS, peptic ulcers, celiac disease), heavy depression, diabetes, heavy liver disease, immunodeficiency, acute cancers within last 3 years except basal cell carcinoma of the skin, etc.)
- •A significant CVD event within last 3 mo. incl. myocardial infarction, stroke, congestive heart failure
- •Regular intake of drugs or supplements possibly interfering with this study (e.g. omega-3, fish oil etc.) within 2 weeks prior to study start or during study
- •Intake of anticoagulants (ASS, Heparin, Marcumar, etc.)
- •General Safety & Laboratory Exclusion Criteria. Patients will be excluded from the study based on the following criteria:
- •- Hemoglobin: <11.0 g/dL (women); <12.0 g/dL (men)
- •- Platelets: <120 x 10^3/µL
- •- Leukocytes <3 x 10^3/mm3
- •- AST or ALT >2.5 x Upper Limit of Normal unless related to primary disease.
- •or further for this study clinically relevant abnormal laboratory findings at screening
- •Are unwilling to abstain from choline-rich foods (e.g. eggs, liver) 3 days prior to blood sampling at V1a and V2a.
- •Pregnancy, breast feeding or intention to become pregnant during the study
研究者
相似试验
尚未招募
不适用
A single-center, randomized, placebo-controlled, two-way crossover study to investigate the drug-drug interaction on the pharmacokinetics and pharmacodynamics of ACT-078573 and single-dose desipramine in healthy male subjectsinsomiasleeplessness10040998NL-OMON32097Actelion Pharmaceuticals20
进行中(未招募)
不适用
A randomised, placebo-controlled, single-centre, double-blind study to evaluate the efficacy, safety and tolerability of topically applied piroxicam gel in patients with recurrent herpes labialisEUCTR2013-003239-31-DEHOV GmbH
未知
1 期
A Single-center, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Assess the Safety and Pharmacokinetics of OPA-15406 Ointment in Healthy Adult Male Subjects (Phase 1 Trial)Atopic DermatitisJPRN-jRCT2080222706Otsuka Pharmaceutical Co., Ltd.32
进行中(未招募)
1 期
Renohemodynamic Effects empaGliflozin in vaRiOUs PopulationsDiabetes Mellitus type 2EUCTR2020-000165-16-NLAmsterdam University Medical Center - location VU Medical Center72
撤回
4 期
A single-center, prospective, placebo-controlled, double-blind, randomized, cross-over mechanistic intervention study to investigate the effect of empagliflozin on kidney function in people with either preserved or impaired kidney function with or without type 2 diabetesType 2 Diabetes MellitusNL-OMON49123Vrije Universiteit Medisch Centrum72
